α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action

Lancet Respir Med. 2021 Apr;9(4):337-339. doi: 10.1016/S2213-2600(21)00018-7. Epub 2021 Jan 21.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 / diagnosis
  • COVID-19 / epidemiology*
  • COVID-19 / genetics
  • COVID-19 Drug Treatment
  • Clinical Trials as Topic
  • Comorbidity
  • Genetic Predisposition to Disease
  • Humans
  • Mutation
  • Risk Factors
  • SARS-CoV-2 / metabolism
  • Serine Endopeptidases / metabolism
  • Serine Proteinase Inhibitors / pharmacology
  • Serine Proteinase Inhibitors / therapeutic use
  • Severity of Illness Index
  • Virus Internalization / drug effects
  • alpha 1-Antitrypsin / genetics*
  • alpha 1-Antitrypsin / metabolism
  • alpha 1-Antitrypsin / pharmacology
  • alpha 1-Antitrypsin / therapeutic use
  • alpha 1-Antitrypsin Deficiency / epidemiology*
  • alpha 1-Antitrypsin Deficiency / genetics

Substances

  • SERPINA1 protein, human
  • Serine Proteinase Inhibitors
  • alpha 1-Antitrypsin
  • Serine Endopeptidases
  • TMPRSS2 protein, human

Grants and funding